An investigational 20-valent pneumococcal conjugate vaccine (20vPnC) made my Pfizer is currently being co-administered with a booster of their COVID-19 vaccine to 600 senior trial participants, given at least six months after their second dose of the COVID vaccine. Participants of the trial all are 65 years and older, they will be followed for six months in order to assess the safety of administering both vaccines together and to track their effects on immunity. Although the need for booster COVID-19 vaccines is not yet known, the immune response to these vaccines is likely to decrease over time. The FDA has pledged to fast-track the approval of booster drugs in order to increase protection against the virus.


For more information, please visit:

Leave a comment

Your email address will not be published. Required fields are marked *